Science
New England Journal Of Medicine Publishes Landmark Phase III Results For Roche’S Itovebi, Showing More Than Doubling Of Progression-Free Survival In Certain Type Of HR-Positive Advanced Breast Cancer
(MENAFN - GlobeNewsWire - Nasdaq) Itovebi TM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or ...
By: menafn
- Oct 31 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS